Scientific Sessions 2024  /  Bridging the Gaps in the Management of Cardiac Amyloidosis - Where are we in 2024?  /  ATTR Genetic Screening and Subsequent Management in Underrepresented Populations-Bridging the Gap 10 minutes
Logo

American Heart Association

  2
  0

Final ID:

ATTR Genetic Screening and Subsequent Management in Underrepresented Populations-Bridging the Gap 10 minutes

  • Ruberg, Frederick  ( Boston University , Boston , Massachusetts , United States )
  • Gillmore, Julian  ( UCL Centre for Amyloidosis , London , United Kingdom )
    • Author Disclosures:
    Frederick Ruberg: DO have relevant financial relationships ; Consultant:Attralus:Active (exists now) ; Research Funding (PI or named investigator):Akcea:Past (completed) ; Research Funding (PI or named investigator):Alnylam:Past (completed) ; Research Funding (PI or named investigator):Anumana:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) | Julian Gillmore: DO have relevant financial relationships ; Consultant:Alnylam, ATTRalus, AstraZeneca, Bridgebio, Lycia, Intellia, Pfizer:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Bridging the Gaps in the Management of Cardiac Amyloidosis - Where are we in 2024?

Sunday, 11/17/2024 , 09:45AM - 11:00AM

Cardiovascular Seminar

More abstracts on this topic:
Role of Artificial Intelligence in Screening and Diagnosis of Cardiac Amyloidosis in a Diverse Patient population 10 minutes

Grogan Martha, Harmon David

5 Key Lessons learned about Cardiac Amyloidosis in the last 10 years and what remains to be learned. 10 minutes

Maurer Mathew, Ambardekar Amrut

More abstracts from these authors:
Discussant: Danon Disease Phase 1 RP-A501

Gillmore Julian, Taylor Matthew, Adler Eric

Building a Multidisciplinary Amyloidosis Program

Ruberg Frederick, Fontana Marianna

You have to be authorized to contact abstract author. Please, Login
Not Available